



SGO 2024 WINTER MEETING

January 25-27, 2024
Olympic Valley, CA

THURSDAY, JANUARY 25, 2024

| Time | Session | Location |
|--------------------|--|----------------------------------|
| 6:30 am - 7:00 am | Registration, Breakfast, Exhibits | Lobby Alcove/ Alpine Ballroom |
| 7:00 am - 8:20 am | Session I: Less is More (de-escalation & preventative care) <i>Moderators: Bradley Corr, MD; Jessica McAlpine, MD</i> | Grand Sierra Ballroom |
| 8:20 am - 8:50 am | Break/Posters/Exhibits | Alpine Ballroom |
| 8:50 am - 10:00 am | Session I (continued): Less is More <i>Moderators: Bradley Corr, MD; Jessica McAlpine, MD</i> | Grand Sierra Ballroom |
| 10:00 am - 3:45 pm | Open Programming Break | |
| 3:45 pm - 4:00 pm | Break/Posters/Exhibits | Alpine Ballroom |
| 4:00 pm - 5:25 pm | Session II: Trials and Tribulations <i>Moderators: Britt Erickson, MD; Travis Sims, MD</i> | Grand Sierra Ballroom |
| 5:25 pm - 5:55 pm | Break/Posters/Exhibits | Alpine Ballroom |
| 5:55 pm - 7:00 pm | Session II (continued): Trials and Tribulations <i>Moderators: Britt Erickson, MD; Travis Sims, MD</i> | Grand Sierra Ballroom |
| 7:00 pm - 8:00 pm | Welcome Reception | Cascades Restaurant |
| 8:00 pm - 9:30 pm | Industry Supported Symposium | Grand Sierra Ballroom |

FRIDAY, JANUARY 26, 2024

| Time | Session | Location |
|--------------------|---|----------------------------------|
| 6:30 am - 7:00 am | Registration, Breakfast, Exhibits | Lobby Alcove/ Alpine Ballroom |
| 7:00 am - 8:20 am | Session III: State of the Science and Controversies <i>Moderators: Mariam Al-Hilli, MD; Susan Modesitt, MD</i> | Grand Sierra Ballroom |
| 8:20 am - 8:50 am | Break/Posters/Exhibits | Alpine Ballroom |
| 8:50 am - 10:00 am | Session III (continued): State of the Science and Controversies <i>Moderators: Mariam Al-Hilli, MD; Susan Modesitt, MD</i> | Grand Sierra Ballroom |
| 10:00 am - 3:45 pm | Open Programming Break | |
| 3:45pm - 4:00pm | Break/Posters/Exhibits | Alpine Ballroom |
| 4:00 pm - 5:20 pm | Session IV: Tumor Board <i>Moderators: Floor Backes, MD; Rob Coleman, MD</i> | Grand Sierra Ballroom |
| 5:20 pm - 5:50 pm | Break/Posters/Exhibits | Alpine Ballroom |
| 5:50 pm - 7:00 pm | Session IV (continued): Tumor Board <i>Moderators: Floor Backes, MD; Rob Coleman, MD</i> | Grand Sierra Ballroom |
| 7:00 pm - 8:00 pm | Networking Reception | Sun & Spa Deck |

SATURDAY, JANUARY 27, 2024

| Time | Session | Location |
|--------------------------------------|--|----------------------------------|
| 6:30 am - 7:00 am | Registration, Breakfast, Exhibits | Lobby Alcove/ Alpine Ballroom |
| 7:00 am - 8:05 am | Session V: It's Getting Hot in Here <i>Moderators: Rebecca Brooks, MD; Alberto Mendivil, MD</i> | Grand Sierra Ballroom |
| 8:05 am - 8:35 am | Break/Posters/Exhibits | Alpine Ballroom |
| 8:35 am - 10:00 am | Session V (continued): It's Getting Hot in Here <i>Moderators: Rebecca Brooks, MD; Alberto Mendivil, MD</i> | Grand Sierra Ballroom |
| 10:00 AM | Meeting Adjourned | |
| | | |
| <i>*Times are subject to change.</i> | | |
| | | |

Abstract Posters - available to view throughout the conference

| Abstract Number | Title | Author |
|-----------------|--|-----------------------|
| 1 - Rapid Fire | CA-125 KELIM Score Predicts Progression-Free and Overall Survival in Patients with Epithelial Ovarian Cancer Undergoing HIPEC at Time of Interval Cytoreductive Surgery | Gabriella Smith |
| 2- Rapid Fire | Homologous Recombination Deficiency Scores Vary by Assay: How can we better harmonize results? | Kaitlyn Kincaid |
| 3- Rapid Fire | Medicaid Expansion and Stage of Cervical Cancer Diagnosis | Sarah Heaps |
| 4- Rapid Fire | Enhancing Sarcopenia Risk Assessment: Markedly Low Serum Creatinine Levels Are Independent Predictors of Major Postoperative Complications in Gynecologic Oncology Patients | Sonya Bharadwa |
| 5- Rapid Fire | A prospective quality improvement initiative for pre-operative risk stratification and individualized lymph node assessment in patients with endometrial intraepithelial neoplasia (EIN) | Pamela Peters |
| 6 | Effect of GLP-1 receptor agonist therapy on endometrial cancer | Danielle Krause |
| 7 | Variations of genomic instability score (GIS) and BRCA mutations with age in ovarian cancer patients | Martins Ayoola-Adeola |
| 8 | ¿Tiene dolor? Tong ma? Exploring the relationship between language, post-operative pain, and opiate use | Rachel Levy |
| 9 | Clinically node-positive cervical cancer: does surgery have a role? | Jenna Zimmerman |
| 10 | Vaginal Brachytherapy Does Not Improve Clinical Outcomes in Uterine Papillary Serous Carcinoma | Vaidehi Mujumdar |
| 11 | Financial toxicity amongst gynecologic oncology surgical patients | Devon Harris |
| 12 | Toxicity predicts response to treatment with lenvatinib/pembrolizumab | Paulina Haight |
| 13 | Incidence of Isolated Tumor Cells in Sentinel Lymph Node in early Cervical Cancer | Katelyn Furey |
| 14 | High-risk histology endometrial cancer and mismatch repair status: The impact of histologic subtype and MLH1 hypermethylation on outcomes. | Courtney Riedinger |
| 15 | Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023 | Taryn Boucher |

| | | |
|----|--|---------------------------|
| 16 | Treatment with a novel inhibitor of tryptophan catabolism attenuates development of an immune suppressed tumor microenvironment by decreasing expression of PD-L1 in ovarian cancer in vitro and in vivo | Jessica Floyd |
| 17 | Unnecessary Exclusion: Eligibility Criteria in Gynecologic Oncology Interventional Clinical Trials Impair Access to Trials | Sharonne Holtzman |
| 18 | Delayed Publication of Gynecologic Oncology Clinical Trials | Alice Darling |
| 19 | Patient Perspective on Virtual Pre-Chemotherapy Visits in Gynecologic Oncology | Monica Janke |
| 20 | Defining the Role of Cannabidiol's Effect in Ovarian Cancer | Ashley Greenwood |
| 21 | Onvansertib exhibits anti-tumorigenic effects in pre-clinical models of endometrioid endometrial cancer | Nikita Sinha |
| 22 | Nutritional status and its Impact on Cervical Cancer Patients treated with Immunotherapy | Julia Chalif |
| 23 | Prognostic Biomarker Validation in High Grade Serous Carcinoma with the Ovarian Tumor Tissue Analysis Consortium and the Multidisciplinary Ovarian Cancer Outcomes Group | Jordyn Tumas |
| 24 | Evaluation of real-world ocular toxicity during treatment with Mirvetuximab soravtansine | Susan Lang |
| 25 | Treatment patterns and outcomes of endometrial cancer patients with uterine-confined high-risk histology | Sarah Lee |
| 26 | Variables impacting postoperative length of stay for gynecologic cancer patients in the era of same day minimally invasive hysterectomy | Margaret Flanigan |
| 27 | The road less traveled: a mixed methods study of patterns and perceptions of training timelines amongst Gynecologic Oncology fellowship applicants, trainees, and graduates | Mary Towner |
| 28 | Racial Disparities in Malignant Cervical Cancer from 2000 to 2020 | Ariel Cohen |
| 29 | Beyond the Scopes: Comparing Patterns and Outcomes in Traditional Laparoscopic Hysterectomy versus Robotic-Assisted Hysterectomy in Stage I Endometrial Cancers | Issac Domenech-Gonzalez |
| 30 | Mental Health in Gynecologic Oncologists: Unmet Needs, Barriers to Care, and Possibilities for Improvement | Rebekah Summey |
| 31 | Assessment of the five factor Modified Frailty Index in predicting postoperative complications and non-home discharge in patients undergoing interval cytoreductive surgery for ovarian cancer | Jennifer Hansen |
| 32 | Characterization of 'High Risk Other' Human Papillomavirus Genotypes | Caitlin Witt |
| 33 | The role of frozen pathology in the evaluation of lymph nodes for endometrial intraepithelial neoplasia: a cost-effectiveness model | Allison Walker |
| 34 | Assessment of the therapeutic use of myeloid growth factors in the treatment of patients with febrile neutropenia and gynecologic malignancies. | Florencia Scaglia Drusini |
| 35 | Trends in estimated percentage of patients with epithelial ovarian cancer eligible for and benefiting from PARP inhibitors over time | Erica Carballo |
| 36 | Response Rates to Immunotherapy in Recurrent & Progressive Endometrial Cancer: The Role of Race and Platinum-Sensitivity | Jennifer Wolf |

| | | |
|----|---|---------------------|
| 37 | Exploring the risk of HSIL conferred by comorbid metabolic conditions in context of oncologic racial disparities | Shreya Raman |
| 38 | Changing Demographics Cervical Cancer in the United States: An Update (2000-2022). | Kassandra Whitfield |
| 39 | Nutritional Risk Index as a prognostic factor in endometrial cancer patients receiving treatment with immunotherapy | Jessica Fulton |
| 40 | Feasibility of Obesity Management with Endocrinology Referral for Prescription of Weight Loss Medications in an Ethnically and Racially Diverse Gynecologic Oncology Clinic | Arjun Sarkar |